Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway
Open Access
- 1 December 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 26 (12) , 2917-2929
Abstract
Kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway (AP) are traditionally classified on the basis of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy appearance (dense deposit disease and C3 GN), or clinical course (atypical postinfectious GN). Each is characterized by an inappropriate activation of the AP, eventuating in renal damage. The clinical diversity of these disorders highlights important differences in the triggers, the sites and intensity of involvement, and the outcome of the AP dysregulation. Nevertheless, we contend that these diseases should be grouped as disorders of the AP and classified on an etiologic basis. In this review, we define different pathophysiologic categories of AP dysfunction. The precise identification of the underlying abnormality is the key to predict the response to immune suppression, plasma infusion, and complement-inhibitory drugs and the outcome after transplantation. In a patient with presumed dysregulation of the AP, the collaboration of the clinician, the renal pathologist, and the biochemical and genetic laboratory is very much encouraged, because this enables the elucidation of both the underlying pathogenesis and the optimal therapeutic approach.Keywords
This publication has 118 references indexed in Scilit:
- Overview of Complement Activation and RegulationSeminars in Nephrology, 2013
- C3 glomerulopathy–associated CFHR1 mutation alters FHR oligomerization and complement regulationJournal of Clinical Investigation, 2013
- Dimerization of complement factor H-related proteins modulates complement activation in vivoProceedings of the National Academy of Sciences, 2013
- Acute Presentation and Persistent Glomerulonephritis Following Streptococcal Infection in a Patient With Heterozygous Complement Factor H–Related Protein 5 DeficiencyAmerican Journal of Kidney Diseases, 2012
- Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulationJournal of Clinical Investigation, 2010
- Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritisThe Lancet, 2010
- Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndromePediatric Nephrology, 2009
- Factor I is required for the development of membranoproliferative glomerulonephritis in factor H–deficient miceJournal of Clinical Investigation, 2008
- Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndromeProceedings of the National Academy of Sciences, 2007
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood, 2006